Free press releases distribution network?

Agency / Source: PRHUB

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Cellworks Group, Inc. Forays into India through R&D Centre in Bangalore - Cellworks Group, Inc., a California based company, has set up its R&D centre in Bangalore, India. Cellworks Research India Limited (CRIL), the R&D centre of Cellworks, would develop and provide technology based solutions that hasten drug discovery
Cellworks Group, Inc. Forays into India through R&D Centre in Bangalore

 

PRZOOM - /newswire/ - Shantinagar, Karnataka, India, 2007/11/14 - Cellworks Group, Inc., a California based company, has set up its R&D centre in Bangalore, India. Cellworks Research India Limited (CRIL), the R&D centre of Cellworks, would develop and provide technology based solutions that hasten drug discovery.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Cellworks Research India Limited (CRIL), the R & D centre of Cellworks, would develop and provide technology based solutions that hasten drug discovery research and development. CRIL’s new facility in Bangalore is STPI approved and has the necessary infrastructure to house 110 scientists.

CRIL’s research focus would be in the areas of oncology, inflammation, metabolic disorders, CNS and Skin. This research based on the Systems Biology approach involves development of in silico platforms of disease physiology at the metabolic and bio-chemical pathway level. This approach enables drug discovery teams to use these platforms as a virtual experimental system. Thus the drug discovery teams would have the benefit of using the in silico system in conjunction with currently used in vitro and in vivo techniques. This besides offering big improvement in productivity would also provide new differentiating capabilities.

Hailing CRIL’s foray into India, Vidya Shankar, IT/BT Secretary, Government of Karnataka, said, “The need to integrate drug mechanism and toxicity within the context of human cellular bio-chemical pathways makes new drug design and discovery a very challenging process and one that is very high up in the pharmaceutical value chain. Incorporation of emergent techniques like in silico based systems biology into the design of new molecules is a much needed innovation. Cellworks with its advanced R&D center in Bangalore is at the forefront of facilitating this paradigm shift in the pharmaceutical industry. Its unique world class team which is a blend of expertise in systems biology, chemistry, computational mathematics, pharma and semiconductor design automation, is perfectly suited to take the lead on this highly innovative initiative.”

Commenting on the successful deployment and usage of Cellworks technology to design new molecules in the oncology area, Dr. Fred Gorin, M.D., PhD, Professor Neurology, University of California, Davis said, "Using Cellworks virtual experimental platforms has revealed the different pathways and mechanisms by which uPA drug or genetic inhibitors affect cell migration, adhesion and attachment. The ability to understand drug mechanism to explain cancer cell death caused by our novel compounds indicates either (1) unaccounted drug targets by our compounds or (2) novel, unpublished pathways by which uPA inhibition is causing selective cancer cell death. Using the predictive technology from Cellworks enabled me to perform "what-if" analysis to test out new hypothesis".

According to Taher Abbasi, CEO and co-founder, Cellworks, “Systems Biology approach will not only hasten drug development by making the process more efficient but also enables researchers to qualify the biological target and associated toxicity at the nascent stage of discovery itself. We are in the process of building one of the largest teams of biology focused researchers in India involved in creation of comprehensive, extensively qualified set of disease aligned virtual platforms and underlying computational engines. Cellworks is committed to grow its collaborations with research teams and customers globally and facilitate deployment of this approach for drug discovery and research.”

Cellworks is among the very early companies in the world and among the first in the Asian region pioneering Systems Biology. With a cross functional team Cellworks strives to create and supply computational biological models of cell systems that can be used to analyze pathways in disease vs. normal conditions. This helps in understanding the effects of probable drugs on pathways within a cell and on cell systems and thereby reduces the chance of drug failure at a later stage, which often proves to be a costly affair.

About Cellworks
Cellworks Group, Inc. is a California Incorporated company with its R&D facility (Cellworks Research India Ltd) based in Bangalore, India. Cellworks adopts a multi-disciplinary and analytical approach to solve biological problems and is part of a new technology wave that will change people’s perception of the diagnosis and treatment of human disease.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: PRHUB

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Cellworks Group, Inc. Forays into India through R&D Centre in Bangalore

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: PRHub 
+91 80 22483007
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any PRHUB securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From PRHUB / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  Intrinsic Executive Search Ltd

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today